摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

13-Methyl-3,4,9,11-tetrazatricyclo[8.4.0.03,7]tetradeca-1(10),4,6,11,13-pentaen-8-one

中文名称
——
中文别名
——
英文名称
13-Methyl-3,4,9,11-tetrazatricyclo[8.4.0.03,7]tetradeca-1(10),4,6,11,13-pentaen-8-one
英文别名
13-methyl-3,4,9,11-tetrazatricyclo[8.4.0.03,7]tetradeca-1(10),4,6,11,13-pentaen-8-one
13-Methyl-3,4,9,11-tetrazatricyclo[8.4.0.03,7]tetradeca-1(10),4,6,11,13-pentaen-8-one化学式
CAS
——
化学式
C11H10N4O
mdl
——
分子量
214.22
InChiKey
WCMDDPMLNBGSQS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    16
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    59.8
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • [EN] NEW ANTIBACTERIAL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTIBACTÉRIENS
    申请人:JANSSEN R & D IRELAND
    公开号:WO2014023815A1
    公开(公告)日:2014-02-13
    The present invention is related to novel compounds of formula (I) that may inhibit the activity of the FabI enzyme, and which are useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
    本发明涉及一种可能抑制FabI酶活性的化合物(I)的新化合物,这些化合物在治疗细菌感染中很有用。还涉及包含这些化合物的药物组合物,以及制备这些化合物的化学过程。
  • NEW ANTIBACTERIAL COMPOUNDS
    申请人:Janssen Sciences Ireland UC
    公开号:EP2882738B1
    公开(公告)日:2017-05-31
  • ANTIBACTERIAL COMPOUNDS
    申请人:JANSSEN SCIENCES IRELAND UC
    公开号:US20150210719A1
    公开(公告)日:2015-07-30
    The present invention is related to novel compounds of formula (I) that may inhibit the activity of the FabI enzyme, and which are useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
  • Antibacterial compounds
    申请人:JANSSEN SCIENCES IRELAND UC
    公开号:US20150225424A1
    公开(公告)日:2015-08-13
    The present invention is related to novel compounds of formula (I) that may inhibit the activity of the FabI enzyme, and which are useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
  • US9296760B2
    申请人:——
    公开号:US9296760B2
    公开(公告)日:2016-03-29
查看更多

同类化合物

氯吡卓醇 利喷西平 丙吡西平 N-[(4-苯基-2,3,4,5-四氢-1H-吡啶并[2,3-b][1,4]二氮杂卓-2-基)甲基]苯甲酰胺 N-[(4-苯基-2,3,4,5-四氢-1H-吡啶并[2,3-b][1,4]二氮杂卓-2-基)甲基]乙酰胺 9-叠氮基-11-乙基-6-甲基吡啶并[3,2-c][1,5]苯并二氮杂卓-5-酮 5-甲基-11-(甲磺酰)-5,11-二氢-6H-二吡啶并[3,2-b:2',3'-e][1,4]重氮基庚英-6-酮 5,11-二氢-4-甲基-6H-二吡啶并[3,2-b:2',3'-e][1,4]二氮杂卓-6-酮 4-苯基-2-氧代-5-(2-(4-甲基哌嗪-1-基)乙酰基)-1H-四氢吡啶并[2,3-b][1,4]二氮杂卓 4-苯基-1,3,4,5-四氢-2H-吡啶并[2,3-b][1,4]二氮杂卓-2-硫酮 4-(吗啉-4-基甲基)-1H-吡啶并[2,3-e][1,4]二氮杂卓-2,3,5(4H)-三酮 4,5-二氢-1H-吡啶并[2,3-E][1,4]重氮基庚英-3(2H)-酮 3-苯基-2-氧代-5-(2-(4-甲基哌嗪-1-基)乙酰基)-1H-四氢吡啶并[2,3-b][1,4]二氮杂卓 3-(乙酰氧基)-7-氯-5-(2-氯苯基)-1,3-二氢-2H-吡啶并[3,2-e]-1,4-二氮杂卓-2-酮 3,4,6,7-四氢-10-氯-1-苯基-8H-吡啶并[3,2,1-jk][1,4]苯并二氮杂卓-4,8-二酮 2-甲基-5-(2-吗啉-4-基乙基)-3,5-二氢-4H-吡啶并[2,3-b][1,4]重氮基庚英-4-酮盐酸 1OH-吡啶并(3,2-d)噻吩并(3,2-e)(1,4)-重氮基庚英-10-酮,4,9-二氢-4-((4-甲基-1-哌嗪基)乙酰基)-,盐酸盐 11-(N-甲基六氢烟酰基)-6,11-二氢-5H-吡啶并(2,3-b)-1,5-苯并二氮杂卓-5-酮 1-(5-甲基-3,4-二氢-2H-吡啶并[2,3-B] [1,4]二氮杂-1-基)乙酮 7,7a,8,9-tetrahydro-5-methyl-5H-pyrido<2,3-b>pyrrole<1,2-d><1,4>diazepin-6,10-dione 2-(3-butoxyphenyl)-1-[8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanone (S,E)-N-methyl-3-(2-methyl-3-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-((3-methylbenzofuran-2-yl)methyl)acrylamide trifluoroacetic acid salt 4-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-d][1,3]diazepin-8-yloxy)butyl methanesulfonate 8-p-tolyl-6,7,9,14,15,16-hexahydroquinoxalino[1,2-a]pyrrolo[2,3-b][1,5]pyridodiazepin-6,7,15-trione 2-(2-furyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-methylphenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-phenyl-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(2-thienyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-bromophenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-fluorophenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-methoxyphenyl)-4-trifluoromethyl-4,5-dihydro-3H-pyrido[2,3-b]diazepin-4-ol 2-(4-methoxyphenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one 2-(4-fluorophenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one 2-(1-naphthyl)-3H-pyrido[2,3-b][1,4]-diazepin-4-one 2-(2-furyl)-3H-pyrido[2,3-b][1,4]-diazepin-4-one 2-(4-bromophenyl)-3H-pyrido[2,3-b][1,4]-diazepin-4(5H)-one 2-(2-thienyl)-3H-pyrido[2,3-b][1,4]-diazepin-4-one 8-chloro-1-methyl-1,2,3,4-tetrahydro-5H-pyrido[2,3-e][1,4]diazepin-5-one 2,3-dihydro-3-hydroxyimino-1-methyl-5-phenyl-1H-pyrido[4,3-e]-1,4-diazepine-2-one 7a,8,9,10-tetrahydro-5-methyldipyrido<2,3-b:1,2-d><1,4>diazepin-6,11(5H,7H)-dione 1-phenyl-2-{(Z)-(4RS)-4-(3-bromo-4,5-dimethoxyphenyl)-1,3,4,5-tetrahydro-2H-pyrido[2,3-b][1,4]diazepin-2-ylidene}-ethanone (+/-)-(R,R)-2-chloro-5-methyl-1,6a,7,8,9,10,10a,11-octahydrobenzo[b]pyrido[2,3-e][1,4]diazepin-4-one (E)-N-methyl-N-((3-methylbenzo[b]thiophen-2-yl)methyl)-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)acrylamide 2-(3-Methoxyphenyl)-1-[8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-4-yl]ethanone 8-Bromo-1,3-dihydro-4,9-dimethyl-2H-pyrido[2,3-b][1,4]diazepin-2-one 5,13-Dimethyl-7,11-diazoniatricyclo[9.4.0.02,7]pentadeca-1(11),2(7),3,5,12,14-hexaene 5-(2-Morpholin-4-yl-ethyl)-2-phenyl-3,5-dihydro-pyrido[3,4-b][1,4]diazepin-4-one 4,9-dihydro-10H-pyrido[3,2-b]thieno[3,2-e][1,4]-diazepin-10-one (10S)-11-acetyl-10-(2,4-dichloro-phenyl)-7,7-dimethyl-5,6,7,8,10,11-hexahydro-3,5,11-triaza-dibenzo[a,d]cyclohepten-9-one (10R)-11-acetyl-10-(2,4-dichloro-phenyl)-7,7-dimethyl-5,6,7,8,10,11-hexahydro-3,5,11-triaza-dibenzo[a,d]cyclohepten-9-one